SCHEMBL24924149

SCHEMBL24924149

CSCc1ccc(C(F)(F)F)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
DAO P14920 1/20 0.42
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
MBOAT4 Q96T53 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
PDE2A O00408 1/20 0.38
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 2/20 0.37
PKM P14618 1/20 0.37
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
TEAD1 P28347 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19557968 0.81 DAO (0.46) KMT2ADAOKDM4ENPSR1KDM1A
SCHEMBL256661 0.79 KMT2A (0.47) KMT2ADAOKDM4ENPSR1KDM1A
SCHEMBL11951542 0.78 KMT2A (0.50) KMT2ADAOKDM4ENPSR1KDM1A
SCHEMBL1787300 0.76 KMT2A (0.39) KMT2ADAOKDM4ENPSR1KDM1A
SCHEMBL10115954 0.76 DAO (0.50) KMT2ADAOKDM1AMAOAMAOB
SCHEMBL10115973 0.76 KMT2A (0.44) KMT2ADAOKDM4ENPSR1KDM1A
SCHEMBL29852337 0.76 DAO (0.50) KMT2ADAOKDM1AMAOAMAOB
SCHEMBL485439 0.75 KMT2A (0.47) KMT2ADAONPSR1KDM1AMAOA
SCHEMBL1311336 0.75 KMT2A (0.47) KMT2ADAOKDM4ENPSR1KDM1A
SCHEMBL472531 0.75 KMT2A (0.52) KMT2ADAOKDM4EKDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists CORCEPT THERAPEUTICS INCORPORATED (US) 2023-10-17 US disclosed
US-20230032612-A1 QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS CORCEPT THERAPEUTICS INCORPORATED 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists NR3C1, NR3C2, MC2R KMT2A 3581/4885DAO 4612/4885KDM4E 3007/4885
US-20230032612-A1 QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, MC2R KMT2A 3581/4885DAO 4612/4885KDM4E 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.